STAT+: Pharmalittle: We’re reading about Wegovy supplies, Biogen ditching Aduhelm, and more
Novo Nordisk is increasing availability of its blockbuster obesity drug Wegovy for new patients in the U.S. after a supply crunch led it to limit doses last May.
Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? And
